CM
HZNP

Castleark Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Castleark Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,495
Closed -$1.32M – 352
2022
Q2 		$1.32M Sell
16,495
-14,265
-46% -$1.35M 0.07% 180
2022
Q1 		$3.24M Sell
30,760
-2,630
-8% -$256K 0.14% 153
2021
Q4 		$3.6M Sell
33,390
-1,740
-5% -$190K 0.13% 157
2021
Q3 		$3.85M Sell
35,130
-5,280
-13% -$548K 0.15% 150
2021
Q2 		$3.78M Buy
40,410
+105
+0.3% +$9.66K 0.13% 157
2021
Q1 		$3.71M Sell
40,305
-1,840
-4% -$155K 0.13% 156
2020
Q4 		$3.08M Sell
42,145
-214,440
-84% -$15.9M 0.12% 160
2020
Q3 		$19.9M Sell
256,585
-92,000
-26% -$6.33M 0.78% 34
2020
Q2 		$19.4M Buy
348,585
+33,030
+10% +$1.41M 0.84% 31
2020
Q1 		$9.35M Buy
+315,555
New +$10.7M 0.55% 50
2019
Q3 		– Sell
-362,980
Closed -$8.73M – 416
2019
Q2 		$8.73M Buy
362,980
+7,442
+2% +$189K 0.34% 101
2019
Q1 		$9.4M Buy
355,538
+62,578
+21% +$1.48M 0.35% 92
2018
Q4 		$5.72M Buy
+292,960
New +$5.74M 0.24% 129
2016
Q4 		– Sell
-478,965
Closed -$8.68M – 435
2016
Q3 		$8.68M Buy
+478,965
New +$9.36M 0.26% 118
2015
Q4 		– Sell
-456,218
Closed -$9.04M – 437
2015
Q3 		$9.04M Sell
456,218
-154,382
-25% -$4.88M 0.29% 93
2015
Q2 		$21.2M Sell
610,600
-908,450
-60% -$27.7M 0.57% 43
2015
Q1 		$39.5M Buy
1,519,050
+917,550
+153% +$16.8M 0.95% 27
2014
Q4 		$7.75M Sell
601,500
-109,428
-15% -$1.37M 0.2% 136
2014
Q3 		$10.7M Buy
710,928
+43,425
+7% +$505K 0.31% 55
2014
Q2 		$10.6M Sell
667,503
-43,425
-6% -$620K 0.29% 60
2014
Q1 		$10.7M Buy
710,928
+210,670
+42% +$2.38M 0.31% 55
2013
Q4 		$3.81M Buy
+500,258
New +$2.7M 0.11% 171

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Castleark Management's HZNP Position: Q3 2022 in Review

Castleark Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 16,495 shares — an estimated $1.32M sold.

Castleark Management first reported a position in HZNP in Q4 2013 and held it in 22 quarters. The position peaked at $39.5M in Q1 2015. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Castleark Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Castleark Management sold 16,495 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $1.32M.
  • Castleark Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 22 quarters.
  • Castleark Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $39.5M in Q1 2015.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Castleark Management's 13F filing for Q3 2022, filed 15 Nov 2022.